Bellerophon up as FDA allows smaller patient group for lung disease drug study

Bellerophon Therapeutics

27/09/2022 15:18

** Drug developer Bellerophon Therapeutics Inc's shares
 BLPH.O  rise 27.7% to $1.24
    ** US FDA has accepted BLPH's proposal to reduce the study
size for its ongoing late-stage trial of therapy for treatment
of type of lung disease  urn:newsml:reuters.com:*:nGNX5n6Gv0
    ** Co says the new data size to not impact the trials main
goal 
    ** Enrollment for the study is now expected to conclude in
Q1 2023, with data from the study to be anticipated in Q3 2023
    ** Up to Monday's close, stock down ~60% YTD
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))